Discounting and decision making in the economic evaluation of health-care technologies
โ Scribed by Karl Claxton; Mike Paulden; Hugh Gravelle; Werner Brouwer; Anthony J. Culyer
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 150 KB
- Volume
- 20
- Category
- Article
- ISSN
- 1057-9230
- DOI
- 10.1002/hec.1612
No coin nor oath required. For personal study only.
โฆ Synopsis
Discounting costs and health benefits in cost-effectiveness analysis has been the subject of recent debate -some authors suggesting a common rate for both and others suggesting a lower rate for health. We show how these views turn on key judgments of fact and value: on whether the social objective is to maximise discounted health outcomes or the present consumption value of health; on whether the budget for health care is fixed; on the expected growth in the cost-effectiveness threshold; and on the expected growth in the consumption value of health. We demonstrate that if the budget for health care is fixed and decisions are based on incremental cost effectiveness ratios (ICERs), discounting costs and health gains at the same rate is correct only if the threshold remains constant. Expecting growth in the consumption value of health does not itself justify differential rates but implies a lower rate for both. However, whether one believes that the objective should be the maximisation of the present value of health or the present consumption value of health, adopting the social time preference rate for consumption as the discount rate for costs and health gains is valid only under strong and implausible assumptions about values and facts. Copyright
๐ SIMILAR VOLUMES
## Abstract The randomised controlled trial (RCT) has developed a central role in applied costโeffectiveness studies in health care as the __vehicle__ for analysis. This paper considers the role of trialโbased economic evaluation in this era of explicit decision making. It is argued that any framew
The inclusion of medical costs in life years gained in economic evaluations of health care technologies has long been controversial. Arguments in favour of the inclusion of such costs are gaining support, which shifts the question from whether to how to include these costs. This paper elaborates on
## Abstract We propose a method for calculating the production costs of an intervention in a manner that accounts for differences in productive โeffort.โ This method could be used within a costโeffectiveness analysis framework in the evaluation of new medical technologies, pharmaceuticals, treatmen
## Abstract Markov models have traditionally been used to evaluate the costโeffectiveness of competing health care technologies that require the description of patient pathways over extended time horizons. Discrete event simulation (DES) is a more flexible, but more complicated decision modelling t